BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37

Benzinga · 2d ago
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.